BSBE(300406)

Search documents
九强生物:中国国际金融股份有限公司关于北京九强生物技术股份有限公司2023年度持续督导工作报告
2024-04-12 07:43
中国国际金融股份有限公司 关于北京九强生物技术股份有限公司 2023 年度持续督导工作报告 中国国际金融股份有限公司(以下简称"中金公司"、"保荐机构")作为北 京九强生物技术股份有限公司(以下简称"九强生物"、"公司")2022 年可转换 公司债券的持续督导机构,根据《证券发行上市保荐业务管理办法》《北京证监 局保荐机构持续督导工作监管指引(试行)》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等相关规定的要求,自 2022 年 7 月 20 日起至 2024 年 12 月 31 日期间,承 担持续督导责任。 现对 2023 年 1 月 1 日至 2023 年 12 月 31 日期间(以下简称"本持续督导 期")的持续督导工作进行总结,情况如下: 一、公司 2023 年生产经营和财务状况、经营环境和行业趋势变化及风险情况 (一)公司生产经营和财务状况 1、公司生产经营情况 2、公司财务状况 2 2023 年度,医疗机构需求恢复,门诊及手术量全面恢复,带动生化及病理试 剂销售增长。与此同时公司不断加大市场开拓力度,拓展销售渠道,寻求新的经 济 ...
九强生物:中国国际金融股份有限公司关于北京九强生物技术股份有限公司2023年持续督导培训工作报告
2024-04-12 07:43
中国国际金融股份有限公司 关于北京九强生物技术股份有限公司 培训内容涵盖上市公司投资者权益保护、股份买卖、关联交易、对外 担保及关联方资金往来、信息披露等;培训涉及的法规主要包括《上市公 司治理准则》《上市公司监管指引第2号——上市公司募集资金管理和使用 的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 2023年持续督导培训工作报告 (2024年4月) | 保荐机构名称:中国国际金融股份有限公司 | 上市公司名称:九强生物 | | --- | --- | | 保荐代表人姓名:雷仁光 | 联系电话:010-65051166 | | 保荐代表人姓名:陈晗 | 联系电话:010-65051166 | 中国国际金融股份有限公司(以下简称"保荐机构")作为北京九强 生物技术股份有限公司(以下简称"九强生物"、"上市公司")2022年 可转换公司债券的保荐机构,根据《证券发行上市保荐业务管理办法》、 《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》等法律、法规的相关规定, 以及上市公司的实际情况,认真履行保荐机构应尽的职责,对上市公司的 董事 ...
九强生物:九强生物2023年度业绩网上说明会记录表
2024-04-11 07:56
会议地点:公司通过全景网"投资者关系互动平台"(https://ir.p5w.net) 采用网络远程的方式召开业绩说明会 会议时间:2024 年 4 月 10 日 15:00—17:00 证券代码:300406 证券简称:九强生物 债券代码:123150 债券简称:九强转债 北京九强生物技术股份有限公司 2023 年度业绩网上说明会记录表 编号:2024-02 投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 其他 ________ 参与单位名称及人 员姓名 参与公司 2023 年度业绩网上说明会的投资者 时间 2024 年 4 月 10 日 15:00—17:00 地点 公司通过全景网"投资者关系互动平台" (https://ir.p5w.net)采用网络远程的方式召开业绩 说明会 上市公司 接待人员姓名 董事长:邹左军 财务总监:刘伟 董事会秘书:王建民 独立董事:陈永宏 投资者关系活动主 要内容介绍 详见会议纪要 附件清单(如有) 无 日期 2024 年 4 月 10 日 1 北京九强生物技术股份有限公司 2023 年度业绩网上说明会会议 ...
九强生物年报点评:业绩增长稳健,国药赋能营销提效
Tai Ping Yang· 2024-04-07 16:00
Investment Rating - The report maintains a "Buy" rating for the company [5][14]. Core Views - The company achieved a revenue of 1.742 billion yuan in 2023, representing a year-on-year growth of 15.27%. The net profit attributable to shareholders was 524 million yuan, up 34.59% year-on-year [2][5]. - The company is expected to see revenue growth of 20% in 2024, with projected revenues of 2.088 billion yuan, and a net profit of 627 million yuan, reflecting a growth rate of 19.7% [5][6]. - The company has successfully recovered its outpatient and surgical volumes, which has driven sales growth in biochemical and pathological reagents [2][14]. Financial Summary - In 2023, the company reported a net operating cash flow of 585 million yuan, a significant increase of 47.69% year-on-year [2]. - The gross profit margin for the company improved to 74.66% in 2023, with a net profit margin of 29.98%, an increase of 3.87 percentage points year-on-year [2][6]. - The company’s earnings per share (EPS) for 2023 was 0.90 yuan, with projections of 1.07 yuan for 2024, 1.31 yuan for 2025, and 1.60 yuan for 2026 [5][6]. Business Development - The company has signed a product distribution agreement with ELITech Group Inc., which is expected to enhance its global market presence with lower sales costs [2][5]. - The company has restructured its business divisions to facilitate resource sharing and collaborative development between its clinical and pathological departments [2][14].
业绩符合预期,持续看好病理业务+国药赋能
ZHONGTAI SECURITIES· 2024-04-01 16:00
Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% in the next 6 to 12 months compared to the benchmark index [14]. Core Insights - The company has shown strong revenue growth, with a 15.27% increase in revenue for 2023, reaching 1,741.63 million yuan, and a net profit growth of 34.59%, amounting to 523.74 million yuan [30][24]. - The collaboration with China National Pharmaceutical Group (Sinopharm) is progressing well, with expectations for more synergies to materialize in 2024, enhancing the company's competitive position in the IVD market [5][23]. - The company has optimized its product structure and reduced operating expenses, leading to improved profitability, with a gross margin of 74.66% and a net margin of 29.98% in 2023 [19][30]. Financial Performance Summary - Revenue for 2023 was 1,741.63 million yuan, a 15.27% increase from 2022 [30]. - The net profit for 2023 was 523.74 million yuan, reflecting a 34.59% year-on-year growth [30]. - The company’s gross margin improved to 74.66%, while the net margin increased to 29.98% [19][30]. - The sales expense ratio decreased to 20.90%, management expense ratio to 8.07%, and financial expense ratio to 2.42% [19][30]. Business Segment Performance - The reagent business generated revenue of 1,634 million yuan, up 14.43% year-on-year, while instrument revenue reached approximately 91 million yuan, growing by 32.29% [23]. - The pathology business achieved revenue of 724 million yuan, a 12.21% increase, demonstrating resilience despite market challenges [23]. - Domestic revenue was 1,710 million yuan, reflecting a 15.42% growth, while overseas revenue was 32 million yuan, up 7.87% [23]. Future Outlook - The company is expected to continue benefiting from the recovery in domestic diagnostic demand, with projections for sustained growth in its biochemical and pathology segments [23][24]. - The financial forecasts indicate a revenue increase to 2,092 million yuan in 2024, with a projected growth rate of 20% [24].
九强生物:关于2024年第一季度可转换公司债券转股情况的公告
2024-04-01 07:49
证券代码:300406 证券简称:九强生物 公告编号:2024-028 债券代码:123150 债券简称:九强转债 北京九强生物技术股份有限公司 关于2024年第一季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没 有虚假记载、误导性陈述或重大遗漏。 特别提示: 1、"九强转债"(债券代码:123150)的转股期限为 2023 年 1 月 6 日至 2028 年 6 月 29 日;最新有效的转股价格为 17.55 元/股。 2、2024 年第一季度,共有 110 张"九强转债"(票面金额共计 11,000 元人 民币)完成转股,合计转成 625 股"九强生物"(股票代码:300406)股票。 3、截至 2024 年第一季度末,公司剩余可转债为 11,210,259 张,剩余票面 总金额为 1,121,025,900 元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定,北京九强生物技术股 份有限公司(以下简称"公司")现将 2024 年第一季度可转换公司债券转股及 公司总股本变化情况公 ...
九强生物:关于回购公司股份的进展公告
2024-04-01 07:47
关于回购公司股份的进展公告 证券代码:300406 证券简称:九强生物 公告编号:2024-027 债券代码:123150 债券简称:九强转债 北京九强生物技术股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司(以下简称"公司") 于 2023 年 7 月 21 日召开的第四届董事会第三十三次(临时)会议审议通过了《关于回购公 司股份方案的议案》,独立董事已对本次回购事项发表了同意的独立意见。 同意公司使用自有资金以集中竞价交易的方式回购部分公司股份,回购股份 后续用于实施股权激励或员工持股计划。本次用于回购的资金总额不低于人 民币 4,000 万元且不超过人民币 8,000 万元,本次回购价格不超过人民币 30 元/股。具体回购股份的数量以回购期满时实际回购的股份数量为准。本次回 购股份的实施期限为自公司董事会审议通过本次回购方案之日起 12 个月内。 公司于 2023 年 7 月 21 日披露了《关于回购公司股份方案的公告》(公告编 号:2023-070)、《回购报告书》(公告编号:2023-071);公司于 202 ...
23Q4业绩亮眼,国药赋能持续推进
EBSCN· 2024-03-31 16:00
Investment Rating - The report maintains a "Buy" rating for the company, reflecting optimism about its strategic development and the ongoing support from its major shareholder, China National Pharmaceutical Group [2][14]. Core Insights - The company has shown significant recovery in its business operations, with a 2023 revenue of 1.742 billion yuan, representing a year-over-year increase of 15.27%. The net profit attributable to shareholders reached 524 million yuan, up 34.60% year-over-year [2][10]. - Research and development investments have increased, with 163 million yuan allocated in 2023, marking an 18.73% growth. The company has also secured 52 patents and 34 medical device registrations during the reporting period [2][10]. - The company has entered the chemiluminescence sector, a recognized high-quality segment in in vitro diagnostics (IVD), with the approval of its fully automated chemiluminescence immunoassay analyzers [2][10]. - The partnership with China National Pharmaceutical Group is expected to enhance the company's internal growth channels and facilitate mergers and acquisitions, thereby boosting its market presence [2][10]. Financial Performance Summary - In Q4 2023, the company reported a revenue of 508 million yuan, a 30.69% increase year-over-year, and a net profit of 152 million yuan, up 27.22% year-over-year [2][10]. - The projected net profits for 2024 and 2025 have been adjusted to 630 million yuan and 763 million yuan, respectively, reflecting a decrease of 6.4% and 8.5% from previous forecasts [2][10]. - The company’s earnings per share (EPS) for 2023 is reported at 0.89 yuan, with projections of 1.07 yuan for 2024 and 1.30 yuan for 2025 [11]. Valuation Metrics - The current price-to-earnings (P/E) ratio is 22, with future projections of 18 for 2024, 15 for 2025, and 12 for 2026 [11][12]. - The company’s return on equity (ROE) is expected to improve from 14.06% in 2023 to 16.40% by 2026 [11]. Strategic Developments - The company has made strategic investments, including acquiring a stake in Longjin Biological Technology Co., which is aimed at further developing its platform capabilities [3]. - The signing of a product distribution agreement with ELITech Group Inc. is anticipated to reduce sales and promotion costs while enhancing brand recognition and expanding overseas market reach [2][10].
九强生物(300406) - 2023 Q4 - 年度财报
2024-03-29 16:00
Product Development and Innovation - The company launched several new antibody reagents for immunohistochemistry, including CA 125, MSH6, and Galectin-3, marking their first introduction during the reporting period[1]. - The new antibody reagents are designed to provide diagnostic assistance to physicians based on routine staining methods[1]. - The company has received 510(k) exemptions for all newly launched antibody reagents, indicating compliance with regulatory standards[1]. - The focus on long-term development for these products suggests a strategic commitment to enhancing diagnostic capabilities in the healthcare sector[1]. - The introduction of these products is expected to expand the company's market presence and enhance its competitive edge in the biotechnology field[1]. - The company is actively collaborating with Fuzhou Maixin Biotechnology Development Co., Ltd. for the development of these new products[1]. - The antibody reagents cover a wide range of applications, indicating a comprehensive approach to immunohistochemistry diagnostics[1]. - The company aims to leverage these new products to drive future revenue growth and market expansion[1]. - The ongoing development of innovative diagnostic tools aligns with the company's strategic vision for long-term sustainability and growth[1]. - The successful launch of these products may lead to increased market share and improved financial performance in the upcoming fiscal periods[1]. - The company has launched 47 medical device registration certificates for new products, including mid-speed and ultra-high-speed automated chemiluminescence analyzers[11]. - The company has developed over 20 reference methods in its reference laboratory, focusing on enzymology, metabolites, proteins, and hormones[8]. - The company is focused on developing high clinical value testing reagents and aims to achieve full coverage of laboratory testing projects[58]. - The company is actively involved in the development of new products, including the vWFAg and anti-Xa reagent kits, which are currently in collaborative research projects with universities[123]. - The company has initiated a national key research and development project focused on the clinical application value of urine PSA for prostate hyperplasia, which started in April 2023[123]. Market Performance and Financials - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2023, representing a year-on-year growth of 15%[114]. - The net profit margin increased to 30.07% in 2023, up from 25.76% in 2022[25]. - The overseas sales revenue grew by 7.87% year-on-year, reflecting the company's expanded international market influence[22]. - The production volume of in vitro diagnostic reagents increased by 25.25% year-on-year, reflecting strong market demand[33]. - The company reported a revenue increase of 15% year-over-year, reaching CNY 1.2 billion in 2023[170]. - New product launches contributed to 30% of total revenue, with three major products introduced in Q3 2023[170]. - Market expansion efforts led to a 40% increase in international sales, now accounting for 15% of total revenue[170]. - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues of CNY 1.32 billion[170]. Research and Development - The company's R&D investment for 2023 was ¥162,898,782.94, an increase of 18.73% compared to 2022[13]. - The company's R&D investment for 2023 amounted to ¥162,898,782.94, representing 9.35% of its operating revenue, an increase from 9.08% in 2022 and 7.94% in 2021[42]. - The R&D investment increased by 20%, amounting to CNY 200 million, focusing on innovative biotechnologies[170]. - The number of R&D personnel increased by 18.12% to 339 in 2023, with a notable rise in the number of bachelor's degree holders[40]. Strategic Partnerships and Collaborations - The company has established strategic partnerships with major firms such as Abbott, Roche, and Hitachi since 2013, enhancing its market position in the IVD sector[7]. - The company is actively collaborating with Fuzhou Maixin Biotechnology Development Co., Ltd. for the development of these new products[1]. - A new strategic partnership was established with a leading biotech firm to co-develop advanced therapies[170]. Governance and Compliance - The company has established a governance structure with a board of directors, supervisory board, and management team to ensure effective decision-making and oversight[106]. - The board of directors consists of 9 members, including 1 chairman and 1 vice chairman, overseeing major investment and strategic decisions[106]. - The supervisory board, composed of 3 members, is responsible for monitoring the actions of directors and management[106]. - The company has implemented a robust governance structure, ensuring compliance with legal requirements and enhancing operational efficiency[117]. - The internal control evaluation report indicates that 100% of the assets and operating income of the evaluated units are included in the consolidated financial statements[138]. - There were no significant defects identified in financial reporting or non-financial reporting during the evaluation period[138]. - The internal control measures established by the company include transaction authorization control, responsibility division control, and budget control, ensuring compliance in business operations[162]. - The company has not identified any significant deficiencies in its internal control during the reporting period[142]. Corporate Social Responsibility - The company has maintained a strong commitment to corporate social responsibility, being recognized as one of the "Top 500 Charitable Enterprises in China" in 2022[125]. - The company is committed to increasing its investment in charitable activities and giving back to society[153]. - The company emphasizes sustainable development, aiming to align short-term and long-term interests while enhancing its social contributions[156]. - The company aims to create more value for society through its charitable actions and contributions[153]. - The company has focused on employee welfare, providing competitive salaries and benefits, and ensuring a harmonious labor relationship[118]. - The company emphasizes environmental protection and sustainability, promoting energy-saving practices and raising awareness among employees[122]. Human Resources and Employee Management - The total number of employees at the end of the reporting period was 1,031, including 619 at the parent company and 412 at major subsidiaries[180]. - The company intends to optimize personnel selection and enhance employee training to build a highly skilled workforce for future growth[81]. - The company has established a performance management framework to enhance the performance evaluation and incentive mechanisms for senior management[189]. - The company has set up a compensation and assessment committee to oversee the performance evaluation of directors and senior management[189]. Financial Management and Investments - The company reported a net cash flow from investing activities increased by 71.14%, primarily due to the recovery of a large certificate of deposit from Mai Xin[61]. - The company has a total of ¥12,407,332.05 in bank deposits as of December 31, 2023, which are frozen as guarantee deposits[47]. - The company reported an investment amount of 5,500,000.00 CNY for the reporting period, a decrease of 95.98% compared to the previous year's investment of 136,775,000.00 CNY[67]. - The company has proposed a share repurchase plan, detailing the purpose, conditions, and funding sources[194]. - The total pre-tax remuneration for the board of directors and senior management amounted to CNY 1,019.18 million[192]. - The chairman, Zou Zuo Jun, received a pre-tax remuneration of CNY 243.44 million, while Liu Xi, a non-independent director, received CNY 201.78 million[192]. Future Outlook and Strategic Goals - The company aims to solidify its leading position in niche markets while accelerating transformation to build an international, comprehensive medical technology platform[57]. - The company plans to enhance market share by analyzing market conditions and policies, and by implementing a collaborative sales strategy of "instruments + reagents"[59]. - The company will adopt a dual approach of internal growth and external mergers and acquisitions to explore high-demand market areas and enhance its product portfolio[78]. - The management team emphasized a commitment to sustainability, targeting a 30% reduction in operational carbon footprint by 2025[170].
九强生物:2023年度监事会工作报告
2024-03-29 11:34
2023 年度监事会工作报告 北京九强生物技术股份有限公司 2023 年度监事会工作报告 2023 年,北京九强生物技术股份有限公司(以下简称"公司")监事会按照《公 司法》《证券法》和《公司章程》的规定,认真履行法律、法规赋予的各项职责,围 绕公司年度生产经营目标切实开展各项工作。公司全体监事恪尽职守、勤勉尽责、努 力工作,保障了公司规范运作和资产及财务的准确完整,维护了公司权益及股东权益。 现将 2023 年监事会工作报告如下: 一、2023 年度公司监事会工作情况 报告期内,共召开 9 次监事会。监事会成员列席了公司 2023 年度历次股东大会 和董事会会议,认真审阅了会议的每一项议案和决议,同时对会议的审议程序进行了 监督,并对决议的贯彻执行进行了监督,全力保证公司治理规范运作。具体情况如下: | 会议届次 | 召开日期 | 会议决议刊登的指定网站 查询索引 | 内容 | 会议决议刊 登的信息披 | | --- | --- | --- | --- | --- | | | | | | 露日期 | | | | | 一、审议通过《关于公司<2022 年度监 | | | | | | 事会工作报告>的议案》; ...